Skip to main content

Walkers advising on Nuvation Bio acquisition of AnHeart Therapeutics in All-Stock Transaction

Mar 22, 2024

Our work
A man in a business suit signing a legal contract.

We are proud to be acting as Cayman Islands counsel to AnHeart Therapeutics, a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, during its merger with Nuvation Bio.

Immediately following the closing of the acquisition, the former shareholders of AnHeart will own approximately 33% and the current stockholders of Nuvation Bio will own approximately 67% of Nuvation Bio on a fully diluted basis.

This acquisition is excepted to close in the second quarter of 2024.

The Walkers team is being led by Cayman Islands based Corporate partner, Hugh Anderson; Corporate senior counsel, Michael Beck; and Corporate associate Samuel Buchan. Davis Polk & Wardwell LLP is acting as lead U.S legal counsel.

Media contact

Jamie Harley

Global Head of Communications

/+44 (0) 7903 051 790

Key contacts

Get in touch with our team

/

Get the latest insights and expertise in your inbox 

Fluid ink image
Sign up